OpenDriver: an open-road driver state detection dataset

In modern society, road safety relies heavily on the psychological and physiological state of drivers. Negative factors such as fatigue, drowsiness, and stress can impair drivers' reaction time and decision making abilities, leading to an increased incidence of traffic accidents. Among the numerous studies for impaired driving detection, wearable physiological measurement is a real-time approach to monitoring a driver's state. However, currently, there are few driver physiological datasets in open road scenarios and the existing datasets suffer from issues such as poor signal quality, small sample sizes, and short data collection periods. Therefore, in this paper, a large-scale multimodal driving dataset for driver impairment detection and biometric data recognition is designed and described. The dataset contains two modalities of driving signals: six-axis inertial signals and electrocardiogram (ECG) signals, which were recorded while over one hundred drivers were following the same route through open roads during several months. Both the ECG signal sensor and the six-axis inertial signal sensor are installed on a specially designed steering wheel cover, allowing for data collection without disturbing the driver. Additionally, electrodermal activity (EDA) signals were also recorded during the driving process and will be integrated into the presented dataset soon. Future work can build upon this dataset to advance the field of driver impairment detection. New methods can be explored for integrating other types of biometric signals, such as eye tracking, to further enhance the understanding of driver states. The insights gained from this dataset can also inform the development of new driver assistance systems, promoting safer driving practices and reducing the risk of traffic accidents. The OpenDriver dataset will be publicly available soon

Cell Therapy Must Be Regulated as Medicine

Background The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy. Case presentation We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens. Conclusion This highly refractory pre-B Ph− ALL was induced to complete remission after one course of single agent blinatumomab

Unleashing the Imagination of Text: A Novel Framework for Text-to-image Person Retrieval via Exploring the Power of Words

The goal of Text-to-image person retrieval is to retrieve person images from a large gallery that match the given textual descriptions. The main challenge of this task lies in the significant differences in information representation between the visual and textual modalities. The textual modality conveys abstract and precise information through vocabulary and grammatical structures, while the visual modality conveys concrete and intuitive information through images. To fully leverage the expressive power of textual representations, it is essential to accurately map abstract textual descriptions to specific images. To address this issue, we propose a novel framework to Unleash the Imagination of Text (UIT) in text-to-image person retrieval, aiming to fully explore the power of words in sentences. Specifically, the framework employs the pre-trained full CLIP model as a dual encoder for the images and texts , taking advantage of prior cross-modal alignment knowledge. The Text-guided Image Restoration auxiliary task is proposed with the aim of implicitly mapping abstract textual entities to specific image regions, facilitating alignment between textual and visual embeddings. Additionally, we introduce a cross-modal triplet loss tailored for handling hard samples, enhancing the model's ability to distinguish minor differences. To focus the model on the key components within sentences, we propose a novel text data augmentation technique. Our proposed methods achieve state-of-the-art results on three popular benchmark datasets, and the source code will be made publicly available shortly

Recent Development in Clinical Applications of PD-1 and PD-L1 Antibodies for Cancer Immunotherapy

Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and PD-L1 antibodies for cancer immunotherapy

Diagnosis and Treatment of CD20 Negative B Cell Lymphomas

CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman\u27s disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL

Clinical Trials of CAR-T Cells in China

Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in China and provided a quick glimpse of the landscape of CAR-T studies in China